In this week’s EuroBiotech Report, Galapagos received a boost ahead of its upcoming Nasdaq IPO when AbbVie placed a provisional order for $30 million (€26 million) in shares, which could be seen as a sign AbbVie will take up its option on rheumatoid arthritis drug filgotinib or buy Galapagos outright. And more.

…read more

Source: AbbVie orders $30M of Galapagos’ IPO, Indivior aces schizophrenia trial, Gilead inks Danish deal


0 No comments